The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.

China-based oncology therapy developer Antengene floated on Friday in an initial public offering sized at about HK$2.79bn ($360m) that achieved exits for corporates WuXi AppTec, Celgene, Taikang and Tigermed, DealStreetAsia reported. The company issued just over 154 million shares on the main board of the Hong Kong Stock Exchange priced at the top of the…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.